{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-253435","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2026-06-02T20:01:13+00:00","discovered_at":"2026-06-02T20:02:00.608600+00:00","generated_at":"2026-06-02T20:02:40.620134+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Tyra Biosciences elects three Class II directors, ratifies Ernst & Young as auditor at 2026 annual meeting","bullets":["Habib J. Dable, Susan Moran, and Robert More elected Class II directors for three-year terms.","Robert More received 41,013,686 for and 3,705,719 withheld (8.3% withheld); Dable and Moran had under 1.1% withheld.","Ernst & Young ratification: 53,092,820 for, 1,316 against, 3,246 abstentions; no broker non-votes on this proposal.","Broker non-votes on director election: 8,377,977 for each director."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-253435","json":"https://secwatch.observer/filing/0001193125-26-253435.json","markdown":"https://secwatch.observer/filing/0001193125-26-253435.md","text":"https://secwatch.observer/filing/0001193125-26-253435.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526253435/0001193125-26-253435-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526253435/d33725d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T20:02:40.620134+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e8a0c6df3bf876d7f147782de27d9e9efa2cc87","claim":"Tyra Biosciences, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-05-28 meeting.","evidence_excerpt":"2. The ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The appointment was ratified by the votes indicated: For Against Abstain Broker Non-Votes 53,092,820 1,316 3,246 –","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526253435/0001193125-26-253435-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-28"}],"fact_type":"shareholder_vote"},{"claim_id":"954317d924fcb4f0361ca354f3450275d2ed05ce","claim":"Tyra Biosciences, Inc. shareholders approved Election of three Class II directors to serve for a three-year term expiring at the 2029 Annual Meeting of Stockholders. at the 2026-05-28 meeting.","evidence_excerpt":"1. The election of three directors to serve as Class II directors for a three-year term to expire at the 2029 Annual Meeting of Stockholders. The following three Class II directors were elected by the votes indicated: For Withheld Broker Non-Votes Habib J. Dable 44,242,803 476,602 8,377,977 Susan Moran, M.D., M.S.C.E. 44,529,688 189,717 8,377,977 Robert More 41,013,686 3,705,719 8,377,977","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1863127/000119312526253435/0001193125-26-253435-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-05-28"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}